1. Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421. (2018) Authors: Lara Jr., P.N.; Plets, M.; Tangen, C.; Gertz, E.; Vogelzang, N.J.; Hussain, M.; Twardowski, P.W.; Garzotto, M.G.; Monk, J.P.; Carducci, M.; Goldkorn, A.; Mack, P.C.; Thompson, I.; Van Loan, M.; Quinn, D.I. Journal: Cancer treatment and research communications Issue: Number 16(2018) Page Start: 18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P0084 Eribulin in patients with advanced urothelial cancer and previously treated with platinum and anti-microtubule chemotherapy: A phase 2 California Cancer Consortium trial. (July 2015) Authors: Quinn, D.I.; Twardowski, P.W.; Ruel, N.; Groshen, S.G.; Dorff, T.B.; Pal, S.K.; Stadler, W.M.; Gandara, D.R.; Lara Jr, P.N.; Newman, E.M. Journal: European journal of cancer Issue: Volume 51(2015)Supplement 2 Page Start: e17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗